Quoin Q3 net loss $2.3M; initiates Peeling Skin Syndrome study; management buys shares

Quoin Pharmaceuticals, Ltd.

Net loss of $2.3M for Q3 2024 vs $1.9M in Q3 2023; nine-month net loss $6.7M vs $6.6M.
Cash and equivalents $10.3M as of Sept 30, 2024; expected to fund operations into late 2025.
Initiates investigator-led clinical study for QRX003 in Peeling Skin Syndrome in New Zealand; no approved treatments exist.
Opens two additional UK sites for Netherton Syndrome trials under FDA IND; plans further European expansion.
Entire management team made significant insider share purchases in September, signaling confidence in growth trajectory.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.